Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
04 April 2022 - 10:30PM
Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a
commercial-stage pharmaceutical company that focuses on the
development and commercialization of pharmaceutical products for
the treatment of dermatological conditions, today announced that
members of Journey Medical’s management team will participate in
the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit
taking place on Tuesday, April 5, 2022 and Wednesday, April 6,
2022. The Summit will be hosted by the B. Riley Securities’
Healthcare Equity Research team and will feature multiple programs
from Fortress’ diversified pipeline.
Journey Medical will present a corporate
overview and participate in a panel discussion on Tuesday, April 5,
2022 at 1:30 p.m. ET. Registration for the event is available
here.
Following the meeting, a webcast of the
company’s presentation will be available on the News and Events
page of the Investors section of Journey Medical’s website,
www.journeymedicalcorp.com, for approximately 30 days after the
meeting.
About Journey Medical
CorporationJourney Medical Corporation (NASDAQ: DERM)
(“Journey Medical”) is focused on identifying, acquiring,
developing and strategically commercializing innovative,
differentiated dermatology products through its efficient sales and
marketing model. The company currently markets nine products that
help treat and heal common skin conditions. The Journey Medical
team is comprised of industry experts with extensive experience in
developing and commercializing some of the most successful
prescription dermatology brands. Journey Medical is located in
Scottsdale, Arizona and was founded by Fortress Biotech, Inc.
(NASDAQ: FBIO). Journey is registered under the Securities Exchange
Act of 1934, as amended, and files periodic reports with the U.S.
Securities and Exchange Commission (“SEC”). For additional
information about Journey Medical, visit
www.journeymedicalcorp.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. As used
below and throughout this press release, the words “we”, “us” and
“our” may refer to Journey Medical. Such statements include, but
are not limited to, any statements relating to our growth strategy
and product development programs and any other statements that are
not historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; uncertainties
relating to preclinical and clinical testing, including the effect
of the current conflict in Europe; risks relating to the timing of
starting and completing clinical trials; our dependence on
third-party suppliers; risks relating to the COVID-19 outbreak and
its potential impact on our employees’ and consultants’ ability to
complete work in a timely manner and on our ability to obtain
additional financing on favorable terms or at all; our ability to
attract, integrate and retain key personnel; the early stage of
products under development; our need for substantial additional
funds; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as may be required by
law, and we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The information contained herein is
intended to be reviewed in its totality, and any stipulations,
conditions or provisos that apply to a given piece of information
in one part of this press release should be read as applying
mutatis mutandis to every other instance of such information
appearing herein.
Company Contacts:Jaclyn Jaffe
and Bill BegienJourney Medical Corporation(781)
652-4500ir@jmcderm.com
Media Relations Contact:Tony
Plohoros6 Degrees(908)
591-2839tplohoros@6degreespr.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024